Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658943 | 0.90 | KMT2A (0.41) | KMT2ATDP1ALDH1A1MAPTF10 | |
| SCHEMBL4806409 | 0.89 | KMT2A (0.51) | KMT2ATDP1ALDH1A1POLBMAPT | |
| SCHEMBL5352406 | 0.88 | KMT2A (0.56) | KMT2ATDP1ALDH1A1POLBMAPT | |
| SCHEMBL5351316 | 0.85 | KMT2A (0.56) | KMT2ATDP1ALDH1A1POLBMAPT | |
| SCHEMBL5353619 | 0.83 | ALDH1A1 (0.49) | KMT2ATDP1ALDH1A1POLBMAPT | |
| SCHEMBL5353653 | 0.83 | KMT2A (0.49) | KMT2ATDP1ALDH1A1POLBMAPT | |
| SCHEMBL5352984 | 0.81 | KMT2A (0.47) | KMT2ATDP1ALDH1A1POLBMAPT | |
| SCHEMBL4807666 | 0.80 | GRIA2 (0.48) | KMT2ATDP1ALDH1A1POLBMAPT | |
| SCHEMBL5641676 | 0.80 | ALDH1A1 (0.48) | KMT2ATDP1ALDH1A1POLBMAPT | |
| SCHEMBL5352404 | 0.80 | KMT2A (0.47) | KMT2ATDP1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253162-B2 | Benzothiazine and benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2007-08-07 | — | — | US | disclosed |
| EP-1486503-B1 | Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20040254161-A1 | New benzothiazine and benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2004-12-16 | — | — | US | disclosed |
| EP-1486503-A1 | Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254161-A1 | New benzothiazine and benzothiadiazine compounds | NR4A1, NR4A3, NR4A2 | KMT2A 396/4885TDP1 1501/4885ALDH1A1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.